VCYT Stock Price Today (October 2026) — Veracyte, Inc. Analysis & Key Metrics 2026-10-20
Veracyte, Inc. (VCYT) is trading at $44.79, up 2.26% today (as of October 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $58.42 (30.4% upside).
- Volatility is high (44.09% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (15.50% YoY) alongside competitive pressures in the Diagnostics & Research space.
VCYT Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Veracyte, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $3.16B
P/E Ratio
Forward P/E: 22.17
Revenue Growth
Year over Year
Analyst Target
+30.4% upside potential
Key Investor Questions About VCYT
What investors need to know before buying
Based on current market data, VCYT presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 53.25)
- Fundamentals say: Looking solid (debt and growth supportive)
VCYT's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VCYT investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $40.11M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, VCYT stock traded between $29.46 and $60.91 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 44.09% annualized volatility and β=1.47, the stock exhibits high sensitivity to market moves—making VCYT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Veracyte's Prosigna Breast Cancer Recurrence Test Gets Medicare Coverage
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Natera Gains 118.1% in a Year: What's Driving the Rally?
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Latest TickZen Insights
All insights →No TickZen article on VCYT yet. Our newest analysis:
Explore More Analysis for VCYT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Veracyte, Inc.
Veracyte, Inc. (VCYT) is currently trading at $44.79. The RSI (14-day) is at 53.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $58.42 implies 30.4% upside from current levels. Volatility is high at 44.1% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Veracyte, Inc. (VCYT): The trailing P/E ratio is 29.44, which is in line with broader market averages. The forward P/E is 22.17, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 2.39. Price-to-Sales is 5.90. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering VCYT, the consensus price target is $58.42. This represents a 30.4% upside from the current price of $44.79. The range spans from a low target of $44.00 to a high target of $70.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Veracyte, Inc. (VCYT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Veracyte, Inc. (VCYT) investors include: 1. High volatility (44.1% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (15.0% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Veracyte, Inc.'s (VCYT) current debt and financial health profile: Total debt stands at $40.11M. The debt-to-equity ratio is 0.03x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 9.16, indicating strong short-term liquidity. The quick ratio is 8.60. The company holds $485.23M in cash and equivalents. Free cash flow is positive at $106.23M, providing a cushion for debt servicing and shareholder returns.